glp 1 slimming & health nano microneedle patch for Weight Loss *r4DAdgBGX* Lenreey® Slimming & health NANO

The first GLP-1 receptor agonist was approved for clinical use by the US Food and Drug Administration on April 28, 2005

Key differences between cagrilintide and semaglutide Mechanism: Cagrilintide: Amylin receptor agonist Semaglutide: GLP-1 receptor agonist Different pathways, complementary effects Gastric emptying: Cagrilintide: Very strong effect (dramatic slowing) Semaglutide: Moderate effect Combined: Maximum slowing Appetite suppression: Cagrilintide: Works via amylin/calcitonin receptors Semaglutide: Works via GLP-1 receptors in brain Combined: Dual-pathway suppression Side effects: Cagrilintide: More nausea/GI effects (stronger gastric slowing) Semaglutide: Moderate GI effects Combined: Higher side effect risk but manageable Approval status: Cagrilintide: Investigational (not approved) Semaglutide: FDA approved CagriSema combination: Phase 3 trials Weight loss monotherapy: Cagrilintide alone: 10-12% body weight loss Semaglutide alone: 10-15% body weight loss Combined: 15-25% body weight loss Why combining cagrilintide and semaglutide works synergistically The combination targets weight loss through multiple pathways

Our professional team of Registered Nurses ensures top-quality service and patient well-being What distinguishes our Vitamin Injections

The underappreciated role of muscle in health and disease

Lola Smallwood-Cuevas Legislator Do we have a sense of a percentage of the workforce that comes through that pathway